News
Vertex absorbs ViaCyte and its stem cell-based diabetes treatment for $320M, clearing out competition. By Max Bayer Jul 11, 2022 11:45am. Vertex Pharmaceuticals ViaCyte CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback